-transparent.png){kind=logo}
The aim of this work was to confirm our preliminary clinical and immunological evaluation of the protective effects of a herpes simplex virus (HSV) vaccine derived from killed virus in the treatment of relapsing facial or genital herpes simplex infection. A total of 142 patients were treated with the HSV vaccine and a control group of 50 were treated with intermittent oral acyclovir (ACV). The vaccine reduced annual active disease days in vaccinees to 11.59 (+/- 15.3) after treatment (65.11 +/- 31.64 before treatment) compared to 30.4 +/- 17.49 days after treatment of the control group patients (71.86 +/- 32.5 before treatment).
Related Publications
A Mastrolorenzo, and
L Tiradritti, and
L Salimbeni, and
G Zuccati
January 1999,
Cornea,
A Mastrolorenzo, and
L Tiradritti, and
L Salimbeni, and
G Zuccati
July 2002,
Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995),
A Mastrolorenzo, and
L Tiradritti, and
L Salimbeni, and
G Zuccati
January 2016,
Proceedings (Baylor University. Medical Center),
A Mastrolorenzo, and
L Tiradritti, and
L Salimbeni, and
G Zuccati
November 1961,
The Journal of pediatrics,
A Mastrolorenzo, and
L Tiradritti, and
L Salimbeni, and
G Zuccati
August 1986,
International journal of oral and maxillofacial surgery,
A Mastrolorenzo, and
L Tiradritti, and
L Salimbeni, and
G Zuccati
February 1965,
Oral surgery, oral medicine, and oral pathology,
A Mastrolorenzo, and
L Tiradritti, and
L Salimbeni, and
G Zuccati
September 1987,
The British journal of ophthalmology,
A Mastrolorenzo, and
L Tiradritti, and
L Salimbeni, and
G Zuccati
September 1964,
British medical journal,
A Mastrolorenzo, and
L Tiradritti, and
L Salimbeni, and
G Zuccati
January 1992,
Annales de dermatologie et de venereologie,
A Mastrolorenzo, and
L Tiradritti, and
L Salimbeni, and
G Zuccati
January 1978,
Infection,
